PROLAX - PWS 370 MG — DIN 02147785
SODIUM CHLORIDE : 370 MG POTASSIUM CHLORIDE : 190 MG SODIUM SULFATE : 1.42 G POLYETHYLENE GLYCOL 3350 : 14.75 G SODIUM BICARBONATE : 420 MG · RIVEX PHARMA INC. · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is PROLAX - PWS?
PROLAX - PWS 370 MG contains SODIUM CHLORIDE : 370 MG POTASSIUM CHLORIDE : 190 MG SODIUM SULFATE : 1.42 G POLYETHYLENE GLYCOL 3350 : 14.75 G SODIUM BICARBONATE : 420 MG. It is listed in the Health Canada Drug Product Database under DIN 02147785, held by RIVEX PHARMA INC., supplied as POWDER FOR SOLUTION for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 15-Oct-2007. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Mineral Salts In Combination in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Mineral Salts In Combination, across 13 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 1 | 1 | PEGLYTE POWDER | Sourceable in Canada |
| GLENDALE AGENCIES | 2 | 0 | EAU PURGATIVE RIGA, RIGA PURGATIVE LEMON FLAV LIQ | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PEGLYTE SOLUTION, PMS-PEGLYTE | No marketed DIN |
| THERAPEX DIVISION DE E-Z-EM CANADA INC | 2 | 0 | LYTEPREP | No marketed DIN |
| ABBOTT LABORATORIES, LIMITED | 1 | 0 | OCL SOLUTION | No marketed DIN |
| BEUTLICH L.P. | 1 | 0 | CEO-TWO BOWEL EVACUANT SUPPOSITORIES | No marketed DIN |
| BRAINTREE LABORATORIES INC. | 1 | 0 | GOLYTELY GI LAVAGE SOLUTION | No marketed DIN |
| RICHMOND PHARMACEUTICALS INC. | 1 | 0 | KLEAN-PREP | No marketed DIN |
| RIVEX PHARMA INC. | 1 | 0 | PROLAX - PWS | No marketed DIN |
| TECHNILAB PHARMA INC. | 1 | 0 | ELECTROPEG SOLUTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 370 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Mineral Salts In Combination |
|---|---|
| ATC code | A06AD10 |
| AHFS class | 56:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02147785 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2147785 |
| Brand name | PROLAX - PWS |
| Generic / active ingredient | SODIUM CHLORIDE : 370 MG POTASSIUM CHLORIDE : 190 MG SODIUM SULFATE : 1.42 G POLYETHYLENE GLYCOL 3350 : 14.75 G SODIUM BICARBONATE : 420 MG |
| Market authorization holder | RIVEX PHARMA INC. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AD10 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AD |
| Current status | CANCELLED POST MARKET |
| Status date | 15-Oct-2007 |
| Original market date | 1996-12-30 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEGLYTE POWDER | 5.85 G | POWDER FOR SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | 00777838 |
| CEO-TWO BOWEL EVACUANT SUPPOSITORIES | 627 MG | SUPPOSITORY | BEUTLICH L.P. | CANCELLED POST MARKET | 02090074 |
| EAU PURGATIVE RIGA | 2.4 G / 30 ML | LIQUID | GLENDALE AGENCIES | CANCELLED POST MARKET | 00421359 |
| ELECTROPEG SOLUTION | 6.7 G / 277 G | POWDER | TECHNILAB PHARMA INC. | CANCELLED POST MARKET | 02230825 |
| GOLYTELY GI LAVAGE SOLUTION | 22.74 G / 4 L | POWDER FOR SOLUTION | BRAINTREE LABORATORIES INC. | CANCELLED POST MARKET | 00652512 |
| KLEAN-PREP | 740 MG | POWDER FOR SOLUTION | RICHMOND PHARMACEUTICALS INC. | CANCELLED POST MARKET | 00741175 |
| LYTEPREP | 25 MMOL | POWDER FOR SOLUTION | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | 00695335 |
| LYTEPREP | 2.97 G | POWDER | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | 02239569 |
| OCL SOLUTION | 1.68 MG | SOLUTION | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | 00709298 |
| PEGLYTE SOLUTION | 1.46 G | LIQUID | PHARMASCIENCE INC | CANCELLED POST MARKET | 00777846 |
2 · Same class — other molecules in ATC A06AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Macrogol | CLARILAX · CLEARLAX · COLAXOR · COMFILAX · +17 more | 22 | 12 | Yes |
| Lactulose | CEPHULAC SYR 667MG/ML · CHRONULAC SYR · CHRONULAC SYR 667MG/ML · COMALOSE R SIROP 10GM/15ML · +20 more | 28 | 5 | Yes |
| Macrogol, Combinations | COLYTE · JAMP-ELECTROPEG · JAMP-ELECTROPEG WITH FLAVOUR PACKET · JAMPLYTE · +3 more | 8 | 3 | Yes |
| Mineral Salts In Combination | CEO-TWO BOWEL EVACUANT SUPPOSITORIES · EAU PURGATIVE RIGA · ELECTROPEG SOLUTION · GOLYTELY GI LAVAGE SOLUTION · +8 more | 13 | 1 | Yes |
| Magnesium Sulphate | EPSOM SALT PWS 100% · EPSOM SALTS · SEL D EPSOM | 6 | 0 | Not in Canada |
| Magnesium Sulphate, Combinations | AGOBYL GRANULE · AGOBYL LIQUIDE · FORMULE 1705 - LIQ | 3 | 0 | Not in Canada |
| Sodium Phosphate | EURO-PHOSPHATES SOLUTION · PHOSPHO-SODA BUFFERED SALINE LAXATIVE · PMS-PHOSPHATES SOLUTION | 3 | 0 | Not in Canada |
| Sorbitol | SORBITOL ROUGIER PWS 5GM | 1 | 0 | Not in Canada |
| Sodium Tartrate | LIMONADE RODECA | 1 | 0 | Not in Canada |
| Magnesium Oxide | MAGNESIUM CITRATE ORAL SOLUTION | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AX | Glycerol · Linaclotide · Lubiprostone · Other Laxatives · Plecanatide · +2 more | 30 | 14 |
| A06AH | Methylnaltrexone Bromide · Naloxegol | 5 | 3 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
| A06AC | Ispaghula (Psylla Seeds) · Ispaghula, Combinations · Linseed · Methylcellulose · Polycarbophil Calcium · +2 more | 79 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.